Axe Compute sells Helomics to DataMEDS in all-stock deal

Axe Compute has sold its legacy Helomics cancer diagnostics lab to DataMEDS AI in an all-stock transaction that gives Axe Compute an equity stake in the health IT company. The deal completes Axe Compute’s shift into a pure-play neocloud GPU-as-a-Service business.

Why it matters: - Axe Compute is shedding its last operating business from its former identity as Predictive Oncology and narrowing its focus to AI infrastructure. - The all-stock structure gives Axe Compute continued upside if DataMEDS expands its oncology and health-data platform. - The transaction aligns the company’s operating structure with demand for GPU-as-a-Service capacity.

What happened: - Axe Compute sold Helomics Corporation, its wholly owned legacy artificial intelligence cancer diagnostics laboratory business, to DataMEDS AI. - The deal was announced Sept. 18, 2026, in Pittsburgh. - Axe Compute received common shares and common share equivalents of DataMEDS as consideration. - Axe Compute said the sale completes its transition to a pure-play neocloud GPU-as-a-Service company.

The details: - Helomics is a Pittsburgh-based functional precision medicine oncology platform that uses artificial intelligence and real-world tumor data to support drug discovery and cancer treatment decisions. - Helomics was the final operating business remaining from Axe Compute’s former identity as Predictive Oncology Inc., before the company changed its name in December 2025. - Christopher Miglino, chief executive officer of Axe Compute, said the company structured the deal so shareholders keep a stake in the future of AI Helomics. - Miglino said Axe Compute is becoming an investor in DataMEDS while focusing team, capital and operations on AI compute demand. - Gerald Commissiong, interim co-CEO of DataMEDS, said the transaction moves DataMEDS into oncology and supports its data-driven healthcare approach. - Axe Compute said more transaction details will appear in a Form 8-K filing with the Securities and Exchange Commission. - The filing will be available at the SEC and on Axe Compute’s investor site. - DataMEDS AI, formerly Wellgistics Health, is a health IT company that says it vertically integrates technology, pharmacy, pharmaceutical-adjacent and telemedicine businesses. - DataMEDS is headquartered in Tampa, Fla. - DataMEDS says its platform includes EinsteinRx™, PharmacyChain™ and the Health Lives Here mobile application. - DataMEDS’ Corexa Health subsidiary provides pharmacy and pharmacy services, including products developed by Tollo Health, LLC.

Between the lines: - The deal removes a non-core legacy asset from Axe Compute’s portfolio and leaves the company more tightly tied to its neocloud strategy. - The equity consideration suggests Axe Compute is betting on the value of DataMEDS’ health-data business instead of taking cash out of the sale. - For DataMEDS, the acquisition adds an oncology asset and a clinical AI use case to a broader health technology stack.

What’s next: - Axe Compute will file the transaction details in an 8-K with the SEC. - The company says it will continue building its GPU-as-a-Service business across compute access and dedicated AI infrastructure offerings. - The market value and liquidity of the DataMEDS shares will affect how much value Axe Compute ultimately realizes from the sale.

The bottom line: - Axe Compute has finished its pivot from a legacy cancer diagnostics business to a focused AI infrastructure company, while keeping a stake in the buyer’s future.